Literature DB >> 22032308

Tanshinone IIA attenuates cyclic strain-induced endothelin-1 expression in human umbilical vein endothelial cells.

Hong-Jye Hong1, Feng-Lin Hsu, Shih-Chang Tsai, Cheng-Hsin Lin, Ju-Chi Liu, Jin-Jer Chen, Tzu-Hurng Cheng, Paul Chan.   

Abstract

1. Tanshinone IIA, one of the active components of the Radix of Salvia miltiorrhiza, is used in traditional Chinese medicine to treat cardiovascular diseases. However, the intracellular mechanism of action of tanshinone IIA remain to be determined. The aims of the present study were to test the hypothesis that tanshinone IIA alters strain-induced endothelin (ET)-1 expression and nitric oxide (NO) production, as well as to identify the putative signalling pathways involved, in human umbilical vein endothelial cells (HUVEC). 2. Cultured HUVEC were exposed to cyclic strain in the presence of 1-10 μmol/L tanshinone IIA. Expression of ET-1 was examined by reverse transcription-polymerase chain reaction and ELISA. Phosphorylation of endothelial NO synthase (eNOS) and activating transcription factor (ATF) 3 was assessed by western blot analysis. 3. Tanshinone IIA (3 and 10 μmol/L) inhibited strain-induced ET-1 expression. In contrast, NO production, eNOS phosphorylation and ATF3 expression were enhanced by tanshinone IIA. The eNOS inhibitor N(G) -nitro-L-arginine methyl ester (l-NAME; 100 μmol/L), the phosphatidylinositol 3-kinase inhibitor LY294002 (5 μmol/L) and the soluble guanylyl cyclase inhibitor 1H-[1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ; 10 μmol/L) inhibited tanshinone IIA-induced increases in ATF3 expression. Moreover, treatment of HUVEC with either an NO donor (3,3-bis [aminoethyl]-1-hydroxy-2-oxo-1-triazene; 500 μmol/L) or an ATF3 activator (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; 5 μmol/L) resulted in the repression of strain-induced ET-1 expression. The inhibitory effect of tanshinone IIA on strain-induced ET-1 expression was significantly attenuated by l-NAME, ODQ and the transfection of small interfering RNA for ATF3. 4. In conclusion, tanshinone IIA inhibits strain-induced ET-1 expression by increasing NO and upregulating ATF3 in HUVEC. The present study provides important new insights into the molecular pathways that may contribute to the beneficial effects of tanshinone IIA in the cardiovascular system.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22032308     DOI: 10.1111/j.1440-1681.2011.05637.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

Review 1.  Therapeutic effects of traditional herbal medicine on cerebral ischemia: a perspective of vascular protection.

Authors:  Youngmin Bu; Kyungjin Lee; Hyuk-Sang Jung; Sang-Kwan Moon
Journal:  Chin J Integr Med       Date:  2013-10-30       Impact factor: 1.978

Review 2.  Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.

Authors:  Zhuo-Ming Li; Suo-Wen Xu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-04-26       Impact factor: 6.150

Review 3.  Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases.

Authors:  Lili Wang; Rufeng Ma; Chenyue Liu; Haixia Liu; Ruyuan Zhu; Shuzhen Guo; Minke Tang; Yu Li; Jianzhao Niu; Min Fu; Sihua Gao; Dongwei Zhang
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 4.  Targeting Oxidative Stress and Endothelial Dysfunction Using Tanshinone IIA for the Treatment of Tissue Inflammation and Fibrosis.

Authors:  Tsuo-Cheng Lu; Yi-Hsiu Wu; Wei-Yu Chen; Yu-Chiang Hung
Journal:  Oxid Med Cell Longev       Date:  2022-04-07       Impact factor: 7.310

5.  Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells.

Authors:  Chung-Yi Lee; Yi-Tin Tsai; Shih-Hurng Loh; Ju-Chi Liu; Tso-Hsiao Chen; Hung-Hsing Chao; Tzu-Hurng Cheng; Jin-Jer Chen
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.